Tag:

non-Hodgkin's lymphoma

Latest Headlines

Latest Headlines

SPOTLIGHT: Cell Therapeutics buys cancer drug

FierceBiotech | August 16, 2007
Cell Therapeutics has agreed to shell out $10 million up front and up to $20 million in milestones for the marketing and development rights of Biogen Idec's

Genzyme reports successful late-stage stem cell study

FierceBiotech | July 19, 2007
Shares of Genzyme were buoyed slightly by the news that Mozobil hit primary and secondary goals in a late-stage trial for non-Hodgkin's lymphoma. The drug spurs the release of bone marrow stem cells

Press Release: Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin’s Lymphoma

FierceBiotech | January 24, 2007
Press Release: Biogen Idec Initiates Phase III Trial of Galiximab for Follicular Non-Hodgkin’s Lymphoma

Seattle Genetics shares soar on Genentech pact

FierceBiotech | January 7, 2007
Shares of Seattle Genetics shot up 31.5 percent this morning after it announced that it would gain $60 million up front and more than $800 million in potential milestones from Genentech from its newly signed development pact for SGN-40. Genentech is committed to pay $20 million of those milestones payments in the first two years of the agreement as Seattle Genetics is reimbursed for clinical trials. The therapy is an early-stage cancer treatment being studied for multiple myeloma, chronic …

New warning issued on Rituxan for lupus

FierceBiotech | December 18, 2006
Biogen Idec and Genentech have warned doctors that two patients taking Rituxan for lupus have died of a rare brain infection called progressive multifocal leukoencephalopathy, or PML. Rituxan is approved for non-Hodgkin's lymphoma and rheumatoid arthritis and cancer patients have already been warned about their risk of PML. One analyst noted that the new risk for lupus may make it harder for the companies to gain approval to use Rituxan for lupus and M.S. Biogen Idec has also had to …

Shire, New River shares surge on FDA approval

FierceBiotech | October 8, 2006
Shares of Shire and New River Pharmaceuticals were on the rise this morning as investors responded to the news that the FDA had approved NRP104, its next generation version of the popular ADHD drug Adderall. New River shares soared 51 percent in early trading as investors considered the impact of a milestone payment of up to $300 million and $100 million in annual bonuses if the drug breaks the billion-dollar revenue mark. Analysts were particularly bullish about the FDA's signal that no …

Millennium to buy AnorMed for $515M

FierceBiotech | September 26, 2006
Cambridge, MA-based Millennium Pharmaceuticals has agreed to pay $515 million to buy Canada's AnorMed, beating out Genzyme for the company. Genzyme had put AnorMed in play with its $380 million offer, but AnorMed signaled from the start that it felt it was worth more. Millennium is buying a company with no approved products but an advanced stem cell therapy, Mozobil, for treating certain types …

Genentech and Biogen Idec in talks over Rituxan

FierceBiotech | August 3, 2006
Genentech and Biogen Idec appear to be at loggerheads over how to develop the blockbuster Rituxan for new uses. Genentech says it will go ahead with plans to develop Rituxan as a therapy for rheumatoid arthritis and another inflammatory disease. But Biogen Idec says it must first approve of the development program. Dow Jones reports that little is known about the disagreement, and a spokesperson for Biogen Idec says they are trying to work things out. Rituxan has successfully …

Favrille wins fast-track designation for cancer drug Favld

FierceBiotech | January 11, 2006
Favrille has won the FDA's fast-track designation for Favld, a treatment for follicular B-cell non-Hodgkin's lymphoma following Rituxan. An ongoing Phase III trial of Favld should produce data on secondary endpoints late this year while primary endpoint data is expected in the second half of 2007. "This decision by the FDA has the potential to save us valuable time in the regulatory approval process, and also serves as an important acknowledgment of the potential for FavId in the …

SPOTLIGHT: Biogen warns on Zevalin

FierceBiotech | October 30, 2005
Biogen Idec has warned that patients taking Zevalin to treat non-Hodgkin's lymphoma can develop severe and sometimes fatal skin reactions. The information has been added to the drug's label and a warning letter has gone out to physicians. Report
Related Tags
Press Releases
  • U.S. FDA Panel Supports Medtronic, Inc. (MDT) Pacemaker
  • Atritech, Inc. Announces FDA Regulatory Update; Confirmatory Study Required for Final FDA Approval
  • FDA APPROVES FIRST OF ITS KIND, FULLY IMPLANTABLE (SURGICALLY), INVISIBLE, PROSTHETIC HEARING RESTORATION DEVICE
  • CryoLife Comments on Status of Medafor Distribution Agreement
  • FDA Statement on Boston Scientific Recall of Implantable Cardioverter Defibrillators
  • More Press Releases
Featured Jobs
  • Global Clinical Operations Study Manager
    Roche Diagnostics - Indianapolis
  • SUPERVISOR FINANCE - 13000007LH
    Abbott - Oakland CA United States
  • Senior Director, Translational Development, Hematology / Oncology Job
    Celgene Corporation - San Francisco CA US
  • SR. DIRECTOR, PHARMACOKINETICS
    Allergan - Allergan Irvine CA
  • SAS Programming - All levels
    Theorem Clinical Research - United States and Canada
Sponsored Links